arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Michelle Clements

9 papers · 2012–2026

2012: 12013: 02014: 02015: 02016: 02017: 02018: 02019: 02020: 12021: 02022: 22023: 12024: 12025: 12026: 2
2012peak 2 in 20222026

Frequent co-authors

Papers

showing 1–9 of 9 RSS

The DURATIONS randomised trial design: estimation targets, analysis methods and operating characteristics

Matteo Quartagno, James R. Carpenter, A. Sarah Walker +2 more

stat.ME · · cited 29× · arXiv ↗ · more like this ·

Background. Designing trials to reduce treatment duration is important in several therapeutic areas, including TB and antibiotics. We recently proposed a new randomised trial design to overcome some of the limitations of standard two-arm non-inferiority trials. This DURATIONS design involves randomising patients to a number of duration arms, and modelling the so-called duration-response curve. This article investigates the operating characteristics (type-1 and type-2 errors) of different statistical methods of drawing inference from the estimated curve. Methods. Our first estimation target is the shortest duration non-inferior to the control (maximum) duration within a specific risk difference margin. We compare different methods of estimating this quantity, including using model confidence bands, the delta method and bootstrap. We then explore the generalisability of results to…

Exploring different objectives in non-inferiority trials

Conor Tweed, Matteo Quartagno, Michelle Clements +5 more

Statistics and Probability · BMJ · · cited 16× · DOI ↗ · more like this ·

Non-inferiority trials compare the efficacy of a new treatment with an existing one where the new treatment is expected to have broadly similar efficacy to the existing treatment, but where other benefits might make the new treatment desirable. These trials might aim to demonstrate that a new treatment is either an alternative to, or a replacement for, the current treatment. In this article, how treatment comparisons can be based only on efficacy, or on both efficacy and other benefits, is explained, and guidance on how to choose the correct objective for a trial is given. This choice should influence the design of the trial (eg, choosing the non-inferiority margin and secondary outcomes), analysis, and reporting of the trial. Most non-inferiority trials aim to show only that a new treatment is an alternative to the standard of care. Being more transparent about the trial objective…

Improving clinical trial interpretation with ACCEPT analyses

Michelle N. Clements, Ian R. White, Andrew J. Copas +7 more

stat.AP · · cited 9× · arXiv ↗ · more like this ·

Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical trials can cause confusion both in trial design and in comparing results across trials. ACceptability Curve Estimation using Probability Above Threshold (ACCEPT) aids comparison between trials (even where of different designs) by harmonising reporting of results, acknowledging different interpretations of the results may be valid in different situations, and moving the focus from comparison to a pre-specified value to interpretation of the trial data. ACCEPT can be applied to historical trials or incorporated into statistical analysis plans for future analyses. An online tool enables ACCEPT on up to three trials simultaneously.

Practical approaches to Bayesian sample size determination in non‐inferiority trials with binary outcomes

Rebecca Turner, Michelle Clements, Matteo Quartagno +6 more

Statistics and Probability · Statistics in Medicine · · cited 6× · DOI ↗ · more like this ·

Bayesian analysis of a non-inferiority trial is advantageous in allowing direct probability statements to be made about the relative treatment difference rather than relying on an arbitrary and often poorly justified non-inferiority margin. When the primary analysis will be Bayesian, a Bayesian approach to sample size determination will often be appropriate for consistency with the analysis. We demonstrate three Bayesian approaches to choosing sample size for non-inferiority trials with binary outcomes and review their advantages and disadvantages. First, we present a predictive power approach for determining sample size using the probability that the trial will produce a convincing result in the final analysis. Next, we determine sample size by considering the expected posterior probability of non-inferiority in the trial. Finally, we demonstrate a precision-based approach. We apply…

How to design a ROCI (Response Over Continuous Intervention) randomised trial: guidance and a case study

Matteo Quartagno, Ehsan Ghorani, Tim P. Morris +8 more

Statistics and Probability · BMC Medical Research Methodology · · cited 0× · DOI ↗ · more like this ·

An important challenge in late-phase drug development is selection of the optimal parameters for treatment administration, including dose, duration and frequency. Whilst these are (near-)continuous parameters, conventional non-inferiority trial designs are not well suited to explore multiple options across a range of values. The ROCI (Response Over Continuous Intervention) randomised trial design is an alternative to standard non-inferiority trials, addressing limitations in selecting optimal treatment regimens, but practical guidance in its application is limited. We outline key design considerations for ROCI trials, including modelling the treatment–response relationship, selecting treatment levels and arms, defining optimality criteria, and determining power and sample size. A flexible fractional polynomial approach is recommended to estimate the treatment–response relationship, and…

Bayesian analysis in confirmatory clinical trials: A narrative review and discussion of current practice

Rebecca Turner, Conor Tweed, Trinh Duong +5 more

Statistics and Probability · Clinical Trials · · cited 0× · DOI ↗ · more like this ·

BACKGROUND: Bayesian methods allow trial investigators to combine evidence obtained within a clinical trial with relevant evidence that is available outside the trial. Bayesian analyses are now widely used in the drug development process, to inform internal 'go/no-go' decisions about planned studies, for example when deciding whether a drug should proceed from phase II to a phase III trial. However, Bayesian analyses are not commonly used for analysis of phase III (confirmatory) trials. METHODS: In this article, we performed a narrative review of confirmatory trials using Bayesian methods for their primary analysis, to explore which types of trials chose Bayesian methods, why they chose a Bayesian analysis and how the methods were used. We reviewed published papers over a 6-year period and explored the characteristics of trials using Bayesian methods for their primary analysis, their…

A Bayesian framework to evaluate non-inferiority in randomized controlled trials of uncommon conditions

Victoria Cornelius, Jack Elkes, Ian R. White +6 more

Statistics and Probability · Journal of Clinical Epidemiology · · cited 0× · DOI ↗ · more like this ·

BACKGROUND AND OBJECTIVES: Noninferiority (NI) trials typically require larger sample sizes than superiority comparisons. This is problematic for uncommon conditions where recruitment is restricted. When a power calculation results in an unfeasibly large sample size, there is a need to justify whether a trial in an uncommon condition is worth undertaking. We propose reversing the question to demonstrate what can be shown with a feasible maximum sample size using a Bayesian framework in place of a traditional power calculation. METHODS: We propose using the posterior probability of noninferiority to demonstrate the value of undertaking an NI trial using a credible NI margin. We describe a five-part Bayesian framework: the data generation/analysis model; maximum feasible sample size; different potential outcomes; primary NI margin; and plausible priors. We illustrate the framework in an…

Improving clinical trial interpretation with Acceptability Curve Estimation (ACE)

Michelle Clements, Ian R. White, Andrew Copas +7 more

Statistics and Probability · UCL Discovery (University College London) · · cited 0× · OpenAlex ↗ · more like this ·

Effective decision making from randomised controlled clinical trials relies on robust interpretation of the numerical results. However, the language we use to describe clinical trials can cause confusion in both trial design and in comparing results across trials. Acceptability curve estimation (ACE) aids comparison between trials (even where of different designs) by harmonising reporting of results, acknowledging different interpretations of the results may be valid in different situations, and moving the focus from comparison to a pre-specified value to interpretation of the trial data. ACE can be applied to historical trials or incorporated into statistical analysis plans for future analyses. An online tool enables ACE on up to three trials simultaneously.

SPECIAL ‘HOW TO... ’ PAPER An ecologist’s guide to the animal model

Alastair J. Wilson, Denis Réale, Michelle N. Clements +5 more

Sociology and Political Science · · cited 0× · OpenAlex ↗ · more like this ·

1. Efforts to understand the links between evolutionary and ecological dynamics hinge on our ability to measure and understand how genes influence phenotypes, fitness and population dynamics. Quantitative genetics provides a range of theoretical and empirical tools with which to achieve this when the relatedness between individuals within a population is known. 2. A number of recent studies have used a type of mixed-effects model, known as the animal model, to estimate the genetic component of phenotypic variation using data collected in the field. Here, we provide a practical guide for ecologists interested in exploring the potential to apply this quantitative genetic method in their research. 3. We begin by outlining, in simple terms, key concepts in quantitative genetics and how an animal model estimates relevant quantitative genetic parameters, such as heritabilities or genetic…